Article: Rituximab-induced acute lympholysis and pancytopenia after COVID-19 vaccination

Rituximab and COVID-19 vaccine can cause massive hyperacute depletion of B cells and plasma cells, as well as subsequent cytokine release syndrome, coagulopathy, and pancytopenia. These effects differ from the adverse effects that have been reported for rituximab, and new guidelines regarding the timing of rituximab infusion and vaccination are urgently needed.

Citing Articles

Therapy in the Course of Kidney Graft Rejection-Implications for the Cardiovascular System-A Systematic Review.

Mizera J, Pilch J, Giordano U, Krajewska M, Banasik M Life (Basel). 2023; 13(7).

PMID: 37511833 PMC: 10381422. DOI: 10.3390/life13071458.

Rituximab-induced acute lympholysis and pancytopenia after COVID-19 vaccination.

Leung V, Lin Y Clin Case Rep. 2021; 9(8):e04517.

PMID: 34429981 PMC: 8365555. DOI: 10.1002/ccr3.4517.

References

1.

Leung V, Lin Y . Rituximab-induced acute lympholysis and pancytopenia after COVID-19 vaccination. Clin Case Rep. 2021; 9(8):e04517. PMC: 8365555. DOI: 10.1002/ccr3.4517. View

2.

Sidner R, Book B, Agarwal A, Bearden C, Vieira C, Pescovitz M . In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies. 2004; 13(3):55-62. View

3.

Selewski D, Shah G, Mody R, Rajdev P, Mukherji S . Rituximab (Rituxan). AJNR Am J Neuroradiol. 2010; 31(7):1178-80. PMC: 7965451. DOI: 10.3174/ajnr.A2142. View

4.

Fajgenbaum D, June C . Cytokine Storm. N Engl J Med. 2020; 383(23):2255-2273. PMC: 7727315. DOI: 10.1056/NEJMra2026131. View

5.

Griffin M, Makris M . Vaccination induced neutropenia. Int J Lab Hematol. 2013; 35(5):e33. DOI: 10.1111/ijlh.12063. View

6.

Kusumoto S, Arcaini L, Hong X, Jin J, Kim W, Kwong Y . Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2018; 133(2):137-146. PMC: 6337873. DOI: 10.1182/blood-2018-04-848044. View

7.

Nazi I, Kelton J, Larche M, Snider D, Heddle N, Crowther M . The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013; 122(11):1946-53. PMC: 3773242. DOI: 10.1182/blood-2013-04-494096. View

8.

Moore D . Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia. P T. 2016; 41(12):765-768. PMC: 5132417. View

9.

Bedognetti D, Zoppoli G, Massucco C, Zanardi E, Zupo S, Bruzzone A . Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol. 2011; 186(10):6044-55. PMC: 3530046. DOI: 10.4049/jimmunol.1004095. View

10.

Paul F, Cartron G . Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol. 2018; 15(4):383-389. DOI: 10.1080/1744666X.2019.1562905. View

11.

Arai Y, Yamashita K, Mizugishi K, Nishikori M, Hishizawa M, Kondo T . Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma. Hematology. 2014; 20(4):196-202. DOI: 10.1179/1607845414Y.0000000188. View

Rituximab-induced Acute Lympholysis and Pancytopenia After COVID-19 Vaccination